4-morpholin-4-yl-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazine-2-carbonitrile | 639854-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-morpholin-4-yl-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazine-2-carbonitrile
• CAS: 639854-21-0
• 化学式: C₁₉H₂₂N₆O₂
• 分子量: 366.423
• InChiKey: KHPHMGJSXDODOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  87.4
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,4-二氯-6-吗啉基-1,3,5-三嗪 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 48.0h， 生成 4-morpholin-4-yl-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazine-2-carbonitrile
  参考文献：
  名称：

  [EN] NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES
  [FR] NOUVELLE UTILISATION DE PYRIMIDINE - OU TRIAZINE- 2-CARBONITILES DESTINES AU TRAITEMENT DE MALADIES LIEES A L'ACTIVITE DE PROTEASE A CYSTEINE ET NOUVEAUX DERIVES DE PYRIMIDINE-2-CARBONITILE

  摘要：

  因此，本发明提供了一种使用化合物(I)和组合物治疗与半胱氨酸蛋白酶活性相关疾病的方法。这些化合物是半胱氨酸蛋白酶S、K、F、L和B的可逆抑制剂。特别感兴趣的是与S半胱氨酸蛋白酶相关的疾病。此外，本发明还揭示了制备这些抑制剂的方法。

  公开号：

  WO2004000819A1

文献信息

• [EN] 2-CYANO-1,3,5-TRIAZINE-4,6-DIAMINE DERIVATIVES<br/>[FR] DERIVES 2-CYANO-1,3,5-TRIAZINE-4,6-DIAMINES
  申请人：AKZO NOBEL NV

  公开号：WO2005011703A1

  公开（公告）日：2005-02-10

  The invention relates to the use of a 2-cyano-1,3,5-triazine -4,6-diamine derivative having general formula (I), wherein R1 is (C1-6)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl, aryloxy(C1-4)alkyl, heteroaryl or heteroaryloxy(C1-4)alkyl; R2 is H or (C1-4)alkyl; or R1 and R2 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR5, which ring may be substituted with (C1-4)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl or NR6R7,and which ring may be fused to a benzene ring; R3 is (C1-6)alkyl, (C3-8) cycloalkyl (optionally comprising 1 or more heteroatoms selected from O, S or NR8), aryl, aryl(C1-4)alkyl or heteroaryl; R4 is H or (C1-4)alkyl; or R3 and R4 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR9; R5, R8 and R9 are independently H, (C1-4)alkyl, (C3-8) cycloalkyl, aryl or aryl(C1-4)alkyl; R6 and R7 are independently H or (C1-4)alkyl; or R6 and R7 form together with the nitrogen to which they are bound a 4-8 membered heterocyclic ring; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of osteoporosis and atherosclerosis.

  该发明涉及使用具有通式（I）的2-氰基-1,3,5-三嗪-4,6-二胺衍生物，其中R1为（C1-6）烷基，（C3-8）环烷基，芳基，芳基（C1-4）烷基，芳氧基（C1-4）烷基，杂芳基或杂芳氧基（C1-4）烷基；R2为H或（C1-4）烷基；或R1和R2与它们结合的氮一起形成一个4-8元杂环，可进一步包括1个或多个来自O、S或NR5的杂原子，该环可能被（C1-4）烷基，（C3-8）环烷基，芳基，芳基（C1-4）烷基或NR6R7取代，并且该环可能与苯环融合；R3为（C1-6）烷基，（C3-8）环烷基（可包括来自O、S或NR8的1个或多个杂原子），芳基，芳基（C1-4）烷基或杂芳基；R4为H或（C1-4）烷基；或R3和R4与它们结合的氮一起形成一个4-8元杂环，可进一步包括1个或多个来自O、S或NR9的杂原子；R5、R8和R9独立地为H，（C1-4）烷基，（C3-8）环烷基，芳基或芳基（C1-4）烷基；R6和R7独立地为H或（C1-4）烷基；或R6和R7与它们结合的氮一起形成一个4-8元杂环；或其药学上可接受的盐，用于制备治疗骨质疏松症和动脉粥样硬化的药物。
• New use of pyrimidine - or triazine - 2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives
  申请人：Bailey Andrew

  公开号：US20050222152A1

  公开（公告）日：2005-10-06

  The present invention therefore provides use of a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition, this invention also discloses processes for the preparation of such inhibitors.

  因此，本发明提供了使用式(I)化合物和组合物治疗与半胱氨酸蛋白酶活性相关的疾病。该化合物是半胱氨酸蛋白酶S、K、F、L和B的可逆抑制剂。特别感兴趣的是与猫hepsin S相关的疾病。此外，本发明还揭示了制备这种抑制剂的过程。
• NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1532121A1

  公开（公告）日：2005-05-25
• US7125881B2
  申请人：——

  公开号：US7125881B2

  公开（公告）日：2006-10-24